Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy
| Autor: | Sandesh C.S. Nagamani, Ying Wang, Rosamund C. Smith, Eric S. Orwoll, Lindsey Nicol, Jay R. Shapiro, Brendan Lee, John H. Sloan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Bone mineral medicine.medical_specialty Anabolism business.industry Endocrinology Diabetes and Metabolism Area under the curve 030209 endocrinology & metabolism medicine.disease Placebo Bone remodeling 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Endocrinology chemistry Osteogenesis imperfecta Internal medicine medicine Teriparatide Sclerostin Orthopedics and Sports Medicine business medicine.drug |
| Zdroj: | Journal of Bone and Mineral Research. 33:307-315 |
| ISSN: | 0884-0431 |
| Popis: | Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age- and sex-matched control participants, mean SOST levels were lower in those with type I or types III/VI OI (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text